Literature DB >> 37257

Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization.

H H Newball, R W Berninger, R C Talamo, L M Lichtenstein.   

Abstract

These studies describe the IgE-mediated relase of a basophil kallikrein-like enzyme that is an arginine esterase and is inhibited by plasma, diisopropylphosphofluoridate, and Trasylol. The substrate specificity for the synthetic amino acid ester substrates p-toluenesulfonyl-L-arginien methyl ester, benzoyl-arginine methyl ester, and acetyl-tyrosine methyl ester is similar for the basophil enzyme and plasma kallikrein. The interaction of arginine esterase-active fractions from ion-exchange (DEAE-Sephacel) and gel filtration (Sepharose 6B) chromatography, with human plasma kininogen, generates immunoreactive kinin. The basophil arginine esterase and kinin-generating activities co-chromatograph on Sepharose 6B and the quantity of kinin generated is, in general, proportional to the arginine esterase activity of the column fractions, suggesting that these two activities are subserved by the same protease. The ability of this protease to generate kinin equally well from heat- and acid-treated plasma, as from fresh human plasma, suggests that this protease has kallikrein-like activity. These data suggest that kallikrein-like activity can be generated from human basophils as a direct result of a primary IgE-mediated immune reaction, thus providing a potential link between reactions of immediate hypersensitivity and the plasma and(or) tissue kinin-generating systems.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37257      PMCID: PMC372140          DOI: 10.1172/JCI109483

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Action of the kallikreins on synthetic ester substrates.

Authors:  M E WEBSTER; J V PIERCE
Journal:  Proc Soc Exp Biol Med       Date:  1961-05

2.  Human kallikrein and prekallikrein.

Authors:  R W Colman; A Bagdasarian
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

Review 3.  Formation of human plasma kinin.

Authors:  R W Colman
Journal:  N Engl J Med       Date:  1974-09-05       Impact factor: 91.245

4.  Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein.

Authors:  R W Colman; L Mattler; S Sherry
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

5.  Mechanisms of passive sensitization. 3. Number of IgE molecules and their receptor sites on human basophil granulocytes.

Authors:  T Ishizaka; C S Soto; K Ishizaka
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

6.  Measurement of molecular weights by electrophoresis on SDS-acrylamide gel.

Authors:  K Weber; J R Pringle; M Osborn
Journal:  Methods Enzymol       Date:  1972       Impact factor: 1.600

7.  Reversible denaturation of enzymes by sodium dodecyl sulfate.

Authors:  K Weber; D J Kuter
Journal:  J Biol Chem       Date:  1971-07-25       Impact factor: 5.157

8.  Kinin-forming activity of human lymphocytes.

Authors:  E G Engleman; L M Greenbaum
Journal:  Biochem Pharmacol       Date:  1971-04       Impact factor: 5.858

9.  Anaphylactic relase of a basophil kallikrein-like activity. II. A mediator of immediate hypersensitivity reactions.

Authors:  H H Newball; R C Talamo; L M Lichtenstein
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

10.  A neutrophil-dependent pathway for the generation of a neutral peptide mediator: partial characterization of components and control by alpha-1-antitrypsin.

Authors:  B U Wintroub; E J Goetzl; K F Austen
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  17 in total

1.  Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

Authors:  D F Rogers; S Dijk; P J Barnes
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy.

Authors:  J N Sharma; A P Yusof
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

3.  Mast cells and basophils: effector cells of inflammatory disorders in the lung.

Authors:  H H Newball; L Lichtenstein
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

4.  Cardiac and pulmonary anaphylaxis in guinea pigs and rabbits induced by glycoprotein isolated from tobacco leaves and cigarette smoke condensate.

Authors:  R Levi; J H Zavecz; J A Burke; C G Becker
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

5.  Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat.

Authors:  F De Clerck; Y Somers; L Van Gorp; B Xhonneux
Journal:  Agents Actions       Date:  1983-02

6.  Hyperosmolar triggering of histamine release from human basophils.

Authors:  S R Findlay; A M Dvorak; A Kagey-Sobotka; L M Lichtenstein
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

7.  Selective antigen-stimulated release of proteolytic activity from rat mast cells.

Authors:  O H Wilhelms
Journal:  Agents Actions       Date:  1980-12

8.  Bradykinin stimulates bone resorption and lysosomal-enzyme release in cultured mouse calvaria.

Authors:  G T Gustafson; U Lerner
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

9.  Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects.

Authors:  S C Christiansen; D Proud; C G Cochrane
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

10.  Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement.

Authors:  A G Togias; R M Naclerio; D Proud; J E Fish; N F Adkinson; A Kagey-Sobotka; P S Norman; L M Lichtenstein
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.